dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

42nd Expert Committee

Sotsiaalministeerium · 30. juuli 2019
Viit
1.4-4/1923-1
Registreeritud
30. juuli 2019
Dokumendi liik
Sissetulev kiri
Adressaat
World Health Organization
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-4 Kutsed ja kirjavahetus rahvusvahelistel seminaridel, konverentsidel jt üritustel osalemiseks
Toimik
1.4-4/2019
Vastutaja
Anna-Liisa Pääsukene (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)
Lahendamise tähtaeg
20. september 2019

Failid

  • 📎C.L.30.2019 (42nd ECDD).pdf109 KB

Sisu (failidest)

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Ref.: C.L.30.2019 The World Health Organization (WHO) presents its compliments to Member States and Associate Members and in reference to C.L.14.2019 has the pleasure of informing that the 42nd Expert Committee on Drug Dependence (ECDD) will meet in Geneva from 21 to 25 October 2019. The Expert Committee on Drug Dependence meetings are of a closed nature, however a public information session on 21 October will be open to Member States. Further information, including a full agenda of the meeting, will be available on the ECDD website: https://www.who.int/medicines/access/controlled-substances/ecdd/ecdd/en/. ... The 42nd ECDD will convene to review psychoactive substances (attached) regarding their potential to cause dependence, abuse and harm to health, and their potential therapeutic applications. WHO will make recommendations to the UN Secretary-General on the need for and level of international control of these substances. Member States are invited to collaborate in this process through designated national focal points, as in the past and in line with the publication “Guidance on the WHO review of psychoactive substances for international control” (EB126/2010/REC1, Annex 6, Para 21). 1 For this purpose, a questionnaire was designed to gather country information on the legitimate use, harmful use, status of national control and potential impact of international control for each substance under evaluation. National focal points designated by Member States following C.L.14.2019 will be approached to complete the questionnaire on substances under review at the 42nd ECDD meeting. Focal points will be given further instructions and direct access to online questionnaires. The questionnaires will be analysed by the Secretariat and prepared as a report that will be shared with the Committee for review. Focal points are also encouraged to provide any additional relevant information (unpublished or published) on substances to be reviewed at the 42nd ECDD to: [email protected] by 20 September 2019. The World Health Organization takes this opportunity to renew to Member States and Associate Members the assurance of its highest consideration. GENEVA, 29 July 2019 1 http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=95. ... ENCL.: (1) 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT 42nd Expert Committee on Drug Dependence (ECDD) 21 to 25 October 2019, WHO headquarters, Geneva, Switzerland Substances under review Critical Review Synthetic cannabinoids 1. APINACA (AKB-48) 2. AB-FUBINACA 3. 5F-AMB (5F-AMB-PINACA, 5F-MMB-PINACA) 4. 5F-MDMB-PICA (5F-MDMB-2201) 5. 4-F-MDMB-BINACA (4F-ADB) Synthetic stimulants 6. 4-CMC (4-chloromethcathinone; clefedrone) 7. N-ethylhexedrone (NEH, Hexen, Ethyl-Hex) 8. Alpha-PHP (PV-7, α-pyrrolidinohexanophenone) 9. DOC (2,5-Dimethoxy-4-chloroamfetamine) Fentanyl Analogues 10. Crotonylfentanyl 11. Valerylfentanyl Benzodiazepines 12. Flualprazolam 13. Etizolam Pre-review Preparations listed in Preparations of: Schedule III of the 1961 Single Convention on o Acetyldihydrocodeine Narcotic Drugs o Codeine o Dihydrocodeine o Ethylmorphine o Nicocodine o Nicodicodine o Norcodeine o Pholcodine when compounded with one or more other ingredients and containing not more than 100 milligrams of the drug per dosage unit and with a concentration of not more than 2.5 per cent in undivided preparations.
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel